Dr. Jonathan Mizrahi, MD

Dr. Mizrahi practices at Ochsner Medical Center - New Orleans in New Orleans, Louisiana, part of Ochsner Health System.

Dr. Mizrahi's NPI, 1467866905, was assigned on June 12, 2014. Dr. Mizrahi graduated from University of Florida College of Medicine in 2014. Dr. Mizrahi holds Louisiana license 323685.

Dr. Mizrahi's primary practice is Ochsner Medical Center - New Orleans, at 1516 Jefferson Hwy, New Orleans, LA 70121 in Jefferson Parish. The practice phone is (504) 842-3000.

Dr. Mizrahi's primary practice is Ochsner Medical Center - New Orleans in New Orleans, Louisiana, part of Ochsner Health System. Dr. Mizrahi is also affiliated with Barnes-Jewish Hospital. The medical group on file is Ochsner Health. Dmand AI also links Dr. Mizrahi to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mizrahi practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mizrahi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Mizrahi's licenses on file in 2 states: Louisiana and Missouri.

CMS data shows 661 Medicare services from Dr. Mizrahi across 4 procedure codes in 2024, for 144 Medicare patients. Medicare paid $46,021 for them.

CMS counts 144 Medicare patients who saw Dr. Mizrahi in 2024. The largest group is 65 to 74, with 77 patients. 75% of them have high blood pressure, and 65% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mizrahi's median patient age at 71, with 52% women.

In 2024, Dr. Mizrahi wrote 793 Medicare Part D claims for 158 patients. 79% of them were for generic drugs. CMS names the drug for 488 of them, across 17 drugs with 11 or more claims each, at $169,164 in total drug cost. In 2023, CMS named 374 claims across 16 drugs.

Dr. Mizrahi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mizrahi as offering telehealth.

Dmand AI links 13 papers to Dr. Mizrahi, published from 2017 to 2024. 2020 was the busiest year, with 4. The most frequent topics are Pancreatic Neoplasms, Antineoplastic Agents and Antineoplastic Combined Chemotherapy Protocols. Dr. Mizrahi has published most often in Nat Commun. Dr. Mizrahi's most frequent co-authors are Shubham Pant, MD, Michael J. Overman, MD and Rachna T. Shroff, MD.

Dmand AI links Dr. Mizrahi to 2 clinical trials, 2 of them phase 1/2 studies. 2 are still active or recruiting. Conditions studied include Pancreatic Neoplasms, Rectal Diseases and Colorectal Neoplasms.

CMS Open Payments shows 236 general payments to Dr. Mizrahi from 26 drug and device companies from 2018 to 2025. Speaker and faculty fees make up the largest share, 56% of the total. AstraZeneca Pharmaceuticals LP paid the most, $101,971.

Dr. Mizrahi graduated from University of Florida College of Medicine in 2014.